Clearmind highlights positive early Phase I/IIa experience for CMND-100 in alcohol use disorder

Investigators from Yale School of Medicine and Johns Hopkins University said the non-hallucinogenic MEAI compound has shown a promising early safety profile, with recruitment advancing despite strict healthy-volunteer criteria.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.